Wave Life Sciences to Webcast Conference Call of First Quarter 2022 Financial Results on May 12, 2022

Rhea-AI Summary

Wave Life Sciences Ltd. (Nasdaq: WVE) has announced a live webcast and conference call scheduled for May 12, 2022, at 8:30 a.m. ET to discuss its first quarter 2022 financial results and provide a business update. The event will be accessible via the company's investor relations website, with teleconference options available for domestic and international participants. Wave Life Sciences focuses on developing life-changing genetic medicines using its proprietary PRISM platform to target genetically defined diseases.

Positive

• Scheduled webcast to discuss first quarter 2022 financial results, showcasing transparency.
• Focus on delivering life-changing treatments may indicate strong future growth potential.

Negative

• None.

CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 12, 2022, to discuss the company’s first quarter 2022 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting “Events” at the investor relations section of the Wave Life Sciences corporate website: ir.wavelifesciences.com. The live teleconference may be accessed by dialing (866) 220-8068 (domestic) or (470) 495-9153 (international) and entering conference ID: 8092347. Following the conference call, an archived version of the call will be available on the website.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit www.wavelifesciences.com and follow Wave on Twitter @WaveLifeSci.

Investor Contact:
Kate Rausch
617-949-4827
krausch@wavelifesci.com

Media Contact:
Alicia Suter
617-949-4817
asuter@wavelifesci.com

FAQ

When will Wave Life Sciences discuss its first quarter 2022 financial results?

Wave Life Sciences will discuss its first quarter 2022 financial results on May 12, 2022, at 8:30 a.m. ET.

How can I access the Wave Life Sciences conference call?

The conference call can be accessed by dialing (866) 220-8068 for domestic calls or (470) 495-9153 for international calls, using conference ID: 8092347.

What is the focus of Wave Life Sciences?

Wave Life Sciences focuses on developing life-changing genetic medicines for genetically defined diseases using its PRISM platform.